

Docket No. JJM5014USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Stephen Bloor

Serial No. : 10/536540

Art Unit: 1615

Filed

: December 5, 2003

Examiner: N/A

For

: WOUND DRESSINGS CONTAINING AN ENZYME THERAPEUTIC

AGENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

December 12, 2005
(Date of Deposit)

Blossom E. Loo (Name of applicant, assignee, or Registered Representative)

/Blossom E. Loo/
(Signature)

December 12, 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

#4

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or []second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10- \Box the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
	n accordance with §1.97(d), this Information Statement is being filed after the mailing date of
	nal Action under §1.113 or a Notice of Allowance
	11 but before the payment of the Issue Fee.
Applicant(s Information) hereby petition(s) for consideration of this Disclosure Statement. Included are: Statement in with §1.97(e) as set forth below and the fee of
\$180.00 as	set forth in §1.17(p).
	opies of each of the references listed on the rm PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTC closed herewith EXCEPT THAT:
1	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner copies are not enclosed herewith.
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
	Copies of only foreign patent documents and non- erature are enclosed in accordance with 37 CFR 1.98

There are no listed references, which are not in the \Box English language. The relevance of those listed references which are 冈 not in the English language is as follows: WEISS & EVERS Aktuelle traumatol (1988) vol. 18(5), pp 219-225, HINZ et al. Fortschr. med. (1984) vol. 102(18) pp. 523-528 and KUHNE et al., Infection (1985) vol. 13(2), pp. 52-56. These references were cited on page 2, lines 9 through 16 of the specification. Attached are copies of search report(s) from 冈 corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending П patent applications, which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JJM5014USNP/BEL. This form is submitted in triplicate. Respectfully submitted, /Blossom E. Loo/ Blossom E. Loo Req. No. 36,858 Attorney for Applicants Johnson & Johnson

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1596 DATED: December 12, 2005



SUBMISSION UNDER MPEP 609 D

12/05/2003 Filing Date First Named Inventor Stephen Bloor 1615 Group Art Unit Examiner Name N/A Attorney Docket Number

Page 1 of 1

Application Number

JJM5014USNP

10/550540

		U.S. PA	IENT DOCUMENTS		
		· ·	U.S. Patent Document		
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
		,			
<u> </u>				,	
A I					
		FOREIGN	PATENT DOCUMENTS		

Pages, Columns, Lines, where relevant passages or relevant figures appear Foreign Patent Document Name of Patentee or Examiner Initials Cite Applicant of Cited Document Number⁴ KindCode⁵ Office³ No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published T² Cite Examiner Initials* International Search Report dated 03/30/2004 Χ

Examiner	Date	l .	
Signature	Considered		





PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays	a valid OMB control number.	
Application Number	10/536540	
Filing Date	12/05/2003	
First Named Inventor	Stephen Bloor	
Group Art Unit	1615	
Examiner Name	N/A	
Attorney Docket Number	JJM5014USNP	

		U.S. Patent Document				
Examiner Initials	Cite		d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear
		4507285		Kuhne	03-26-1985	
		4576817		Montgomery	03-18-1986	
		4614794		Easton et al.	09-30-1986	
		4851222		Kuhne et al.	07-25-1989	
		2001/0041188		Gibbins et al.	11-15-2001	
		2002/0018802		Beiersdorf	02-14-2002	· · · · · ·
			·			

FOREIGN PATENT DOCUMENTS Foreign Patent Document **Date of Publication** Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant Тв mm-dd-yyyy Applicant of Cited Document Initials figures appear Office³ Number⁴ KindCode5 No.1 91/08793 **A1** WO Brigham and Women's X 06/27/1991 Hospital 0541391 EP **B1** Johnson & Johnson X 06/10/1998 Medical, Inc. 0918548 EP **B1** Johnson & Johnson 01/02/2003 X Medical, Inc.

Examiner	Date		
Signature	Considered	The second second	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a valid OMB control number.
10/536540
12/05/2003
Stephen Bloor
1615
N/A
JJM5014USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		WEISS & EVERS Aktuelle traumatol (1988) vol. 18(5), pp 219-225.	
		HINZ et al. Fortschr. med. (1984) vol. 102(18) pp. 523-528.	
		KUHNE et al., Infection (1985) vol. 13(2), pp. 52-56.	
	ļ		
	ļ		
	ļ		
	<u> </u>		
			
3			
			ļ
			<u> </u>
·····			
	•		ļ
			L

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.